[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prostate-cancer-stage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prostate-cancer-stage":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100548311","early-phase-1-99mtc-qulic-5-p1-spect-imaging-in-patients-with-prostate-cancer-100548311",false,"NCT06419348","99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer","99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer and Compared With 68Ga-PSMA-11 PET","Inclusion Criteria:\n\n1. At least 18 years of age.\n2. Signed informed consent.\n3. Patients with suspected or newly diagnosed or previously prostate cancer, with PSMA positive expression (supporting evidence may include MRI, CT, and pathology report, etc).\n\nExclusion Criteria:\n\n1. Patients with PSMA negative expression.\n2. Patients with pregnancy.\n3. The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.\n4. Known or expected hypersensitivity to 99mTc-QULIC-5-P1 or any of its components.\n5. Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.",true,"MALE","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","99mTc-QULIC-5-P1 is a new radiotracer targeting PSMA, which is promising as an excellent imaging agent applicable to PSMA positive prostate cancer. This study will investigate the safety, biodistribution and potential usefulness of 99mTc-QULIC-5-P1 SPECT imaging for the diagnosis of lesions in PSMA positive prostate cancer.",[27,28,29],"Prostate Cancer Stage","PSMA","SPECT","RECRUITING","2025-05-29",{"date":33,"type":34},"2025-06-04","ACTUAL",{"date":36,"type":34},"2024-05-20",{"date":38,"type":21},"2026-12-31",{"name":40,"class":41},"First Affiliated Hospital of Chongqing Medical University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":16,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":42},"100567017","artificial-intelligence-models-for-precision-prediction-and-treatment-of-prostate-cancer-100567017","NCT06662708","Artificial Intelligence Models for Precision Prediction and Treatment of Prostate Cancer","Accurate Prediction and Treatment of Prostate Cancer by Artificial Intelligence Model-based Whole Slide Images and MRIs","Inclusion Criteria:\n\n* Patients with suspected PCa (elevated PSA or suspicious positive lesions on ultrasound or MRI results);\n\nExclusion Criteria:\n\n* Previous treatment of the prostate in any form, including surgery, radiotherapy\u002Fchemotherapy, endocrine therapy, targeted therapy and immunotherapy;\n* Patients with any item missing from the baseline clinical and pathological information;\n* Patients with a history of other malignancies, serious comorbidities or other health problems;\n* Unable to provide\u002Fsign an informed consent form;\n* Patients who, in the judgement of the investigator, are deemed unfit to participate in this clinical trial;","30 Years",{"count":52,"type":21},200,[54],"NA","The aim of this clinical trial is whether artificial intelligence models can be used for accurate clinical preoperative diagnosis and postoperative diagnosis of pathological findings, and will also measure the accuracy of the predictions made by the artificial intelligence models.The main target questions addressed by the model building are:\n\n1. whether the AI model can learn from preoperative MRI and postoperative Whole Slide Images so as to accurately predict information such as benignness or malignancy, aggressiveness, grading, subtypes, genes, etc. for participants suspected of having prostate cancer preoperatively\u002Fpuncturally.\n2. whether the AI model is capable of learning postoperative macropathology slides to enable outcome diagnosis of surgical pathology slides in new participants.\n\nParticipants will:\n\n1. complete an MRI examination and have their MRI images analysed by the established AI model to make an accurate diagnosis of them.\n2. Based on the diagnosis, if prostate cancer is predicted, they will undergo radical prostate cancer surgery and refine their surgical pathology.",[57,58,59,27,60],"Prostate Cancer","Prostate Intraductal Carcinoma","Prostate Cancer Aggressiveness","Pathology",[62,63,64,57,65],"Articicial Intelligence","Whole Slide Image","mp-MRI","Prediction Model","NOT_YET_RECRUITING","2024-10-27",{"date":69,"type":34},"2024-10-29",{"date":71,"type":21},"2024-12-01",{"date":73,"type":21},"2030-12-31",{"name":75,"class":41},"Shao Pengfei",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":83,"minAge":84,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":42},"100554299","binaural-sound-for-remimazolam-maintenance-100554299","NCT06497283","Binaural Sound for Remimazolam Maintenance","The Effect of Intraoperative Binaural Sound on Remifentanil Dose Required for General Anesthesia Using Remimazolam: a Randomized, Placebo-controlled Trial","Inclusion Criteria:\n\n1. Patients scheduled for general anesthesia\n2. Patients aged 20-60\n3. Patients with American Society of Anesthesiologist physical status classification 1-2\n4. Patients with ideal body weight 50-80 kg\n\nExclusion Criteria:\n\n1. Patients with hearing disability\n2. Patients using opioids or sedatives in 1 week\n3. Patients who are dependent for alcoholics or drugs\n4. Patients with hypersensitivities to remimazolam or remifentanil\n5. Patients with arrhythmia, cardiovascular disease, heart failure, or hypovolemia\n6. Patients with liver failure","ALL","20 Years",{"count":86,"type":21},72,[54],"It is important to decrease the remifentanil dose for general anesthesia maintenance when using remimazolam. We will evaluate the effect of binaural sound on general anesthesia maintenance with remimazolam infusion.",[90,27,91],"General Anesthesia","Uterine Myoma","2024-08-07",{"date":94,"type":34},"2024-08-09",{"date":96,"type":34},"2024-07-12",{"date":98,"type":21},"2025-02-28",{"name":100,"class":41},"Gangnam Severance Hospital"]